Clinical Trials Arena on MSN
Takeda unveils secondary endpoint data from Phase III PsO pill trials
The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results